American Financial Group, Inc. Management to Participate in the 2025 Keefe, Bruyette & Woods Insurance Conference
While there will be no Company presentation, AFG will host several investor meetings. The investor material to be used in the meetings will be posted via a link under Events on the Investor Relations page of AFG's website, www.AFGinc.com, just prior to the conference.
About American Financial Group, Inc.
American Financial Group is an insurance holding company, based in Cincinnati, Ohio. Through the operations of Great American Insurance Group, AFG is engaged primarily in property and casualty insurance, focusing on specialized commercial products for businesses. Great American Insurance Group's roots go back to 1872 with the founding of its flagship company, Great American Insurance Company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Tecnoglass Responds to Short Seller Report
Company Categorically Rejects All Allegations Which it Believes to be False, Misleading and Malicious Company Reaffirms Recently Increased Full Year 2025 Guidance Miami, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Tecnoglass, Inc. (NYSE: TGLS) ("Tecnoglass" or the "Company"), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today issued the following statement in response claims made in a short seller report: Tecnoglass categorically rejects what it believes are false, misleading, and unsubstantiated allegations contained in the report. Tecnoglass believes the publication is a clear attempt to manipulate the market and harm the Company's shareholders. The report largely focuses on previous claims that were thoroughly reviewed and addressed in 2022 by a Special Committee of the Company's independent Board members, with the support of highly respected external legal and accounting advisors. That review concluded with no evidence of wrongdoing, fraud, or financial misstatement. Tecnoglass remains committed to highest standards of ethical conduct, transparency and sound corporate governance. The Company is reviewing all available options, including potential legal action against parties responsible for disseminating the report, to protect the interests of Company shareholders and the integrity of the market. The Company will continue to cooperate fully with regulators and stakeholders, as it always has, and will not allow unfounded speculation or attempts to manipulate the market to distract from the Company's mission of building long-term value for customers, employees, and shareholders. The Company reaffirmed its recently increased full year 2025 financial guidance announced on August 7, 2025 that reflects the Company's solid performance through the first half of 2025 and the continued strength across the business and belief that the business will achieve another year of strong profitability and cash generation. Reflecting confidence in the strength and long-term prospects of the business, Tecnoglass also notes that its active share repurchase program will be used when appropriate, underscoring management's belief that the Company's fundamentals and growth outlook are not reflected in the current market price. Tecnoglass remains focused on delivering exceptional, best-in-class services and solutions for our residential and commercial customer base, and delivering long-term value for our shareholders. About Tecnoglass Tecnoglass Inc. is a leading producer of high-end aluminum and vinyl windows and architectural glass serving the multi-family, single-family, and commercial end markets. Tecnoglass is the second largest glass fabricator serving the U.S. and the #1 architectural glass transformation company in Latin America. Located in Barranquilla, Colombia, the Company's 5.8 million square foot, vertically integrated, and state-of-the-art manufacturing complex provide efficient access to nearly 1,000 customers in North, Central and South America, with the United States accounting for 95% of total revenues. Tecnoglass' tailored, high-end products are found on some of the world's most distinctive properties, including One Thousand Museum (Miami), Paramount (Miami), Salesforce Tower (San Francisco), Via 57 West (NY), Hub50House (Boston), Aeropuerto Internacional El Dorado (Bogotá), One Plaza (Medellín), Pabellon de Cristal (Barranquilla). For more information, please visit or view our corporate video at Forward Looking Statements This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future financial performance, future growth and future acquisitions. These statements are based on Tecnoglass' current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive and/or regulatory factors, and other risks and uncertainties affecting the operation of Tecnoglass' business. These risks, uncertainties and contingencies are indicated from time to time in Tecnoglass' filings with the Securities and Exchange Commission. The information set forth herein should be read in light of such risks. Further, investors should keep in mind that Tecnoglass' financial results in any particular period may not be indicative of future results. Tecnoglass is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events and changes in assumptions or otherwise, except as required by law. Investor Relations: Santiago GiraldoCFO305-503-9062investorrelations@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
3 minutes ago
- Business Wire
L3Harris Expands Florida Facility to Support America's Golden Dome
MELBOURNE, Fla.--(BUSINESS WIRE)--L3Harris Technologies (NYSE: LHX) has completed a $100 million expansion at its satellite integration and test facility in Palm Bay to support the Department of Defense's (DOD) urgent need for on-orbit technology for the Golden Dome for America. L3Harris' new investment in Florida adds to the existing capability of the Space Coast and will enable key components for this strategic capability to be delivered during President Trump's second term. Elected officials, customers and business leaders participated in a ribbon-cutting ceremony today for the expanded 94,000-square-foot facility, designed to produce next-generation satellites that will identify, track and defend against hypersonic and advanced missile threats. 'Accelerating the production of proven hardware for national missile warning and defense remains a priority as we align resources across the enterprise to support the President's vision for America's Golden Dome,' said Christopher E. Kubasik, Chair and CEO, L3Harris. 'We continue to deliver advanced space-based technology with the speed and agility required to protect our homeland from advanced threats while bolstering U.S. manufacturing and continued investment in Florida.' L3Harris currently provides crucial missile warning and missile defense capabilities with five satellites on orbit and 34 satellites being developed for hypersonic missile tracking in support of the DOD's current missile warning and missile defense architecture. 'Thank you for what you do every day for our country. It's so exciting to see a new facility opening in Palm Bay, Florida,' said U.S. Rep. Mike Haridopolos. 'L3Harris is an instrumental leader, not just in space, but national defense, as you're a vital part of the Golden Dome.' L3Harris has invested hundreds of millions of dollars in infrastructure and manufacturing processes across the United States to deliver national defense capabilities at the pace and scale required. 'Palm Bay is honored to be the home of this advanced facility, which plays a vital role in strengthening our national security and sustaining the technological edge that keeps our country safe,' said Palm Bay Mayor Rob Medina. 'The investment by L3Harris not only supports key defense and space missions but also drives economic opportunity here at home through high-skill, high-wage jobs. We're proud that Palm Bay is helping lead the way in supporting our nation's readiness and innovation. L3Harris remains a valued partner in that mission and in the continued growth of our city.' L3Harris' investments translate to more than 900,000 square feet of new and renovated advanced manufacturing space nationwide to support the production of space-based missile warning and defense technologies, precision fire-control sensing, targets, and propulsion and control systems for interceptors. About L3Harris Technologies L3Harris Technologies is the Trusted Disruptor in the defense industry. With customers' mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains in the interest of national security. Visit for more information. Forward-Looking Statements This press release contains forward-looking statements that reflect management's current expectations, assumptions and estimates of future performance and economic conditions. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The company cautions investors that any forward-looking statements are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements. Statements about technology capabilities are forward-looking and involve risks and uncertainties. L3Harris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
22 minutes ago
- Yahoo
My Top Dividend-Paying, Deep-Value Stock to Buy in August
Key Points Pfizer offers the highest forward dividend yield in the healthcare sector. The stock trades at an exceptionally attractive valuation. Pfizer faces some challenges but should continue to survive and thrive as it has for 176 years. 10 stocks we like better than Pfizer › What's better than a stock that pays great dividends? How about one that's also a bargain? Granted, most strong dividend stocks aren't available at a discount in the current high-flying market. However, that doesn't mean you can't find them at all. I can think of several dividend-paying, deep-value stocks to buy in August. One stock stands at the top of my list: pharmaceutical giant Pfizer (NYSE: PFE). Pfizer's juicy dividend Pfizer's forward dividend yield currently stands at 6.86%. This yield is so attractive that I wondered if it's the highest of any healthcare stock. It is (or was recently, anyway). As of Aug. 19, 2025, Pfizer's forward dividend yield was the juiciest in the healthcare sector. The big drugmaker's dividend track record is impressive, too. Pfizer has paid 347 consecutive quarterly dividends. The company has increased its dividend for 16 consecutive years. Can Pfizer keep the dividends flowing and growing? I think it can. So does the company's management team. CFO David Denton reiterated in Pfizer's second-quarter earnings call that the dividend program remains first on the drugmaker's capital allocation priorities, stating, "Our strategy consists of maintaining and growing our dividend over time." Sure, Pfizer's dividend payout ratio of around 90% is higher than I'd like. However, the pharmaceutical company's earnings continue to grow. Pfizer even recently raised its full-year earnings guidance. It's also on track to cut costs by around $7.2 billion by the end of 2027, which will further improve the bottom line and the payout ratio. A tremendous value Let's shift gears to discuss Pfizer's tremendous value. The stock's forward price-to-earnings (P/E) ratio is only 8.3. That's a fraction of the S&P 500's forward earnings multiple of 22.8. It's also well below the S&P 500 healthcare sector's average forward P/E of 16.5. One question comes to mind, though: Is Pfizer a value trap? After all, the drugmaker faces a patent cliff with several of its top-selling products losing patent exclusivity over the next few years. The list includes blood thinner Eliquis, which generated nearly $7.6 billion for Pfizer last year, and breast cancer drug Ibrance, which raked in almost $4.4 billion in sales. I think Pfizer is in a better position than meets the eye to navigate its patent cliff. The company has several new products with strong growth prospects, notably including migraine drug Nurtec ODT, RSV vaccine Abrysvo, and multiple myeloma drug Elrexfio. Pfizer's pipeline also features 108 candidates, with 28 late-stage programs and four awaiting regulatory approvals. Wall Street seems to agree that Pfizer isn't a value trap. The consensus 12-month price target reflects an upside potential of over 13%. Pfizer's price-to-earnings-to-growth (PEG) ratio, which is based on five-year earnings growth projections of analysts surveyed by LSEG, is a low 0.86. This PEG ratio suggests that analysts aren't overly concerned about Pfizer's growth prospects, even with multiple drugs losing exclusivity. Some risks Pfizer does face some risks. Although I believe it will weather the patent cliff relatively well, the losses of exclusivity make the company more dependent on the success of its new drugs and pipeline programs. Sometimes, new drugs don't perform as well as expected. Pipeline candidates can also sometimes flop in clinical trials. President Trump's threatened pharmaceutical tariffs could negatively impact Pfizer. So could his administration's push to implement "most-favored-nation" drug pricing, which aims to tie U.S. drug prices to the lowest prices paid by other developed nations. Again, though, I think Pfizer will survive and thrive -- just as it has for 176 years. For investors seeking high dividend yields and deep value, I view Pfizer as the best pick on the market right now. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. My Top Dividend-Paying, Deep-Value Stock to Buy in August was originally published by The Motley Fool Sign in to access your portfolio
